IRRAS AB – Year-end Report 2017 – invitation to conference call and webcast
Stockholm, Sweden, 10.00 CET, February 20, 2018 – IRRAS, a commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, will publish its Year-end Report for January-December 2017 on Wednesday, February 21, 2018 at 07.30 a.m. CET.
The Company will also host a conference call and an online presentation on the same day (Wednesday, February 21, 2018) at 08:00 a.m. CET.
The dial-in numbers for the conference call are:
SE: +46 8 5063 9549
UK: +44 20 3008 9807
The presentation will also be webcast and can be accessed from the following web address:
Hosts: President CEO Kleanthis G Xanthopoulos, Ph.D. and CFO and Deputy CEO Fredrik Alpsten
Investor and Media Contact:
CFO and Deputy CEO
+46 706 67 31 06
Notes to Editor
IRRAS is a commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, with a goal of dramatically improving patient outcomes, reducing patient-time in the intensive care unit and medical ward, and providing significant health economic benefits to hospitals and healthcare providers.
The Company’s initial product focus is on intracranial fluid management solutions that utilize its proprietary platform technology, IRRAflow, which is a CE-marked, fully integrated, closed-circuit medical device system that enables intelligent intracranial fluid management as well as accurate, real-time monitoring of intracranial pressure.
With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS maintains its headquarters in Sweden with corporate offices in Germany and La Jolla, CA, USA.
IRRAS started to sell IRRAflow in Europe the summer 2017. A 510 (k) application was submitted in June 2017. IRRAS is traded on the Nasdaq First North Premier in Stockholm under the symbol IRRAS.
The information was released for public disclosure, through the agency of the contact person above, on February 20 at 10.00 a.m. (CET).